Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2895680 | 1.00 | TSHR (0.45) | TSHRMAPTNPC1ADRB2ADRB1 | |
| SCHEMBL1327171 | 0.83 | MAPT (0.60) | TSHRMAPTNPC1ADRB2ADRB1 | |
| SCHEMBL17005472 | 0.83 | MAPT (0.60) | TSHRMAPTNPC1ADRB2ADRB1 | |
| SCHEMBL2306548 | 0.83 | MAPT (0.60) | TSHRMAPTNPC1ADRB2ADRB1 | |
| SCHEMBL22365152 | 0.83 | CASR (0.47) | TSHRNPC1ADRB2ADRB1ADRB3 | |
| SCHEMBL16710538 | 0.81 | TSHR (0.45) | TSHRNPC1ADRB2ADRB1ADRB3 | |
| SCHEMBL16707862 | 0.81 | TSHR (0.44) | TSHRNPC1ADRB2ADRB1ADRB3 | |
| SCHEMBL20224963 | 0.81 | TSHR (0.41) | TSHRMAPTNPC1ADRB2ADRB1 | |
| SCHEMBL16724859 | 0.80 | TSHR (0.42) | TSHRNPC1ADRB2ADRB1ADRB3 | |
| SCHEMBL2567290 | 0.74 | L3MBTL1 (0.57) | GAAALDH1A1KDM4EGLASLC2A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440666-B2 | Pyridazinone compounds and P2X7 receptor inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES LIMITED | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | P2RY1, P2RX7, P2RX1 | TSHR 989/4885MAPT 4114/4885NPC1 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.